Last reviewed 2026-04-22 · How we verify

Capsaicine low dose 0.04 %

Capsaicin activates TRPV1 nociceptors on nerve fibers, causing initial stimulation followed by desensitization and reduced pain signal transmission.

Capsaicin activates TRPV1 nociceptors on nerve fibers, causing initial stimulation followed by desensitization and reduced pain signal transmission. Used for Neuropathic pain (localized), Postherpetic neuralgia, Musculoskeletal pain.

At a glance

Mechanism of action

Capsaicin is a vanilloid compound that binds to and activates the transient receptor potential vanilloid 1 (TRPV1) channel on C-fiber nociceptors. Repeated or sustained exposure leads to desensitization of these pain-sensing neurons, reducing their ability to transmit pain signals. At low doses in topical formulations, this results in localized analgesia without systemic effects.

Approved indications

• Neuropathic pain (localized)
• Postherpetic neuralgia
• Musculoskeletal pain

Common side effects

• Local burning or stinging at application site
• Erythema
• Pruritus

Key clinical trials

• Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After Surgery (PHASE3)
• Capsaicin in Digital Osteoarthritis Versus Control (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Capsaicine low dose 0.04 % CI brief — competitive landscape report
• Capsaicine low dose 0.04 % updates RSS · CI watch RSS
• University Hospital, Clermont-Ferrand portfolio CI